Eli Lilly (NYSE: LLY) has been a top growth stock in the healthcare industry for years. The company's vast pipeline and diverse business have allowed it to continue to find ways to grow -- and Trulicity has been a key growth catalyst for the business in recent years.

But now, other drugs are growing at much faster rates today and could soon eclipse Trulicity in revenue. Let's see what this could all mean for Eli Lilly and its shareholders.

Diabetes drug Trulicity generated more than $7.4 billion in revenue for Eli Lilly last year, accounting for more than one-quarter of the company's top line, which totaled $28.5 billion. 

Continue reading

Source Fool.com